The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors.

Goodis CC, Eberly C, Chan AM, Kim M, Lowe BD, Civin CI, Fletcher S
Eur J Med Chem. 2024 Dec 22;285:117190. doi: 10.1016/j.ejmech.2024.117190. PubMed Article

Plasmids from Article

ID	Plasmid	Purpose
227688	pMJK2243	Empty lentivector to overexpress gene of interest
227690	BCL2alpha-MJK2243	Expresses human BCL2alpha